Inhaled ethyl nitrite prevents hyperoxia-impaired postnatal alveolar development in newborn rats

Am J Respir Crit Care Med. 2007 Aug 1;176(3):291-9. doi: 10.1164/rccm.200605-662OC. Epub 2007 May 3.

Abstract

Rationale: Inhaled nitric oxide (NO) has been used to prevent bronchopulmonary dysplasia, but with variable results. Ethyl nitrite (ENO) forms S-nitrosothiols more readily than does NO, and resists higher-order nitrogen oxide formation. Because S-nitrosylation is a key pathway mediating many NO biological effects, treatment with inhaled ENO may better protect postnatal lung development from oxidative stress than NO.

Objectives: To compare inhaled NO and ENO on hyperoxia-impaired postnatal lung development.

Methods: We treated newborn rats beginning at birth to air or 95% O(2) +/- 0.2-20.0 ppm ENO for 8 days, or to 10 ppm NO for 8 days. Pups treated with the optimum ENO dose, 10 ppm, and pups treated with 10 ppm NO were recovered in room air for 6 more days.

Measurements and main results: ENO and NO partly prevented 95% O(2)-induced airway neutrophil influx in lavage, but ENO had a greater effect than did NO in prevention of lung myeloperoxidase accumulation, and in expression of cytokine-induced neutrophil chemoattractant-1. Treatment with 10 ppm ENO, but not NO, for 8 days followed by recovery in air for 6 days prevented 95% O(2)-induced impairments of body weight, lung compliance, and alveolar development.

Conclusions: Inhaled ENO conferred protection superior to inhaled NO against hyperoxia-induced inflammation. ENO prevented hyperoxia impairments of lung compliance and postnatal alveolar development in newborn rats.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Animals
  • Animals, Newborn
  • Bronchodilator Agents / administration & dosage*
  • Bronchodilator Agents / adverse effects
  • Bronchopulmonary Dysplasia / prevention & control
  • Disease Models, Animal
  • Humans
  • Hyperoxia / drug therapy
  • Hyperoxia / physiopathology
  • Infant, Newborn
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Nitric Oxide / administration & dosage
  • Nitric Oxide / adverse effects
  • Nitrites / administration & dosage*
  • Nitrites / adverse effects
  • Oxidative Stress / drug effects
  • Pulmonary Alveoli / drug effects*
  • Pulmonary Alveoli / growth & development*
  • Pulmonary Alveoli / pathology
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Bronchodilator Agents
  • Nitrites
  • Nitric Oxide
  • ethyl nitrite